Screening for Down syndrome at 14 weeks of pregnancy
| Autor: | Hilary Watt, James E. Haddow, Nicholas J. Wald, G J Knight |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
endocrine system
Fetus medicine.medical_specialty Down syndrome Pregnancy Neural tube defect Obstetrics business.industry Chorionic gonadotrophin Obstetrics and Gynecology Gestational age Aneuploidy medicine.disease medicine business Trisomy hormones hormone substitutes and hormone antagonists Genetics (clinical) |
| Zdroj: | Prenatal Diagnosis. 18:291-293 |
| ISSN: | 1097-0223 0197-3851 |
| DOI: | 10.1002/(sici)1097-0223(199803)18:3<291::aid-pd244>3.0.co;2-8 |
| Popis: | To investigate whether statistical parameters used in Down syndrome screening between 15 and 22 weeks of pregnancy can be used at 14 weeks, we assayed alpha-fetoprotein (AFP), unconjugated oestriol (uE3), total human chorionic gonadotrophin (hCG), free alpha-hCG, free beta-hCG, and inhibin-A in 16 pregnancies with Down syndrome in the 14th week of pregnancy and expressed values in multiples of the normal median. The median and standard deviation values for these 16 pregnancies were not materially different from those published for 15-22 weeks. It is reasonable, therefore, to offer Down syndrome screening using these markers starting at 14 completed weeks of pregnancy instead of 15 weeks. It needs to be recognized, however, that serum AFP measurement for neural tube defect screening is less effective at this time than between 16 and 18 weeks of pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text